Cell & Gene Exchange, May 2017: Research Cancer Institute of America/Pacific Medical Center of Hope

June 16, 2017
Research Cancer Institute of America (RCIA) has established a novel concept and team of scientific experts in oncology and has developed related therapeutic products. It is appraised (estimated value) at USD 200 million, and owns several patents approved by US and European patent offices. The technology (method) and products have shown superior pre-clinical AND clinical implications in a variety of tumors (both solid tumors and hematological cancers). The molecular mechanism of the therapy is unique as it targets the cancer stem cells; there is no commercially available product for the same or similar targets in the market. It is expected that the ideal pharmaceutical partner will assist in FDA approval process and commercialization. The goal is strategic partnership to further develop, manufacture and commercialize our products used in a range of cancer treatments. Optionally a partner could also be a pharmaceutical company with interest in development of combinational therapies. Contact: megan@allcancercare.com Speaker: M. A. Nezami – President
Previous Video
Cell & Gene Exchange, May 2017: BrainStorm Cell Therapeutics
Cell & Gene Exchange, May 2017: BrainStorm Cell Therapeutics

BrainStorm Cell Therapeutics (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous ste...

Next Video
Cell & Gene Exchange, May 2017: Asymmetrex, LLC
Cell & Gene Exchange, May 2017: Asymmetrex, LLC

Asymmetrex is a Massachusetts life sciences company with a focus on developing technologies to advance stem...